Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA

Key Points

• Seven Fleet Capital Management increased its Savara stake by 371.1% in the first quarter, reaching 295,688 shares valued at approximately $1.61 million. Institutional investors collectively own 87.93% of the company.
• Analyst sentiment is generally positive, with a consensus rating of “Moderate Buy” and an average price target of $10.14, compared with Savara’s recent trading price near $5.46.
• Savara reported a quarterly loss of $0.15 per share, slightly worse than the $0.14 consensus estimate. The clinical-stage biopharmaceutical company is focused on rare respiratory diseases, including its lead candidate Molgradex for autoimmune pulmonary alveolar proteinosis.

Seven Fleet Capital Management LP raised its position in shares of Savara Inc. (NASDAQ:SVRA - Free Report) by 371.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 295,688 shares of the company's stock after purchasing an additional 232,926 shares during the quarter. Seven Fleet Capital Management LP owned 0.14% of Savara worth $1,614,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Prudential Financial Inc. bought a new stake in Savara during the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets grew its holdings in Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock valued at $31,000 after buying an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in Savara in the 2nd quarter valued at $33,000. Russell Investments Group Ltd. grew its holdings in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after buying an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in Savara in the 3rd quarter worth approximately $44,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Oppenheimer started coverage on shares of Savara in a research note on Friday, April 24th. They issued an "outperform" rating and a $11.00 price objective for the company. Wall Street Zen raised shares of Savara from a "sell" rating to a "hold" rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Savara presently has an average rating of "Moderate Buy" and a consensus price target of $10.14.

Savara Trading Down 1.4%

SVRA opened at $5.46 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. The stock's 50 day moving average price is $5.58 and its 200-day moving average price is $5.51. Savara Inc. has a one year low of $2.43 and a one year high of $7.01. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -9.75 and a beta of 0.24.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). On average, equities analysts forecast that Savara Inc. will post -0.57 EPS for the current year.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.